Next Wave of IPOs: Companies Going Public in 2026

Quick Glance at What's Ahead

Why 2026 Could Be a Banner Year for IPOs
Top Sectors Poised for Public Listings
Spotlight on AI & Tech Giants
Healthcare & Biotech: A New Generation
Fintech Unicorns Preparing for Market
How to Spot Promising IPO Candidates
Frequently Asked Questions about 2026 IPOs

After a rollercoaster in the IPO market over the past few years, 2026 is shaping up to be a pivotal year. I've been tracking the pipeline closely, and let me tell you — the sheer number of high-quality companies waiting in the wings is staggering. We're not just talking about your run-of-the-mill startups; these are mature, revenue-heavy unicorns with real business models. In this piece, I'll walk you through the sectors and specific companies I believe will make headlines, plus share some hard-learned lessons on separating hype from substance.

You've probably heard the phrase "IPO window opening." Well, in 2026, I expect that window to be thrown wide open. Here's why: The backlog of companies that postponed listings in 2022-2024 has built up enormous pressure. Many of them have spent those years shoring up their financials, cutting costs, and waiting for market volatility to settle. Now, with interest rates stabilizing and investor appetite returning, the conditions are ripe. I personally attended a few pre-IPO roadshows last quarter, and the vibe was electric — VCs are pushing their portfolio companies to go public, and the underwriters are practically licking their chops.

Another factor: the rise of new listing venues. The Hong Kong Exchange and Nasdaq are competing fiercely for tech listings, while the London Stock Exchange is trying to lure fintechs. This competition means friendlier rules and faster timelines. Expect a flood of filings in the first half of 2026.

Top Sectors Poised for Public Listings

If I had to bet on which industries will dominate the 2026 IPO calendar, it'd be these three: artificial intelligence (especially enterprise AI), healthcare/biotech (with a focus on gene editing), and fintech (embedded finance and blockchain). Let's dig into each.

Enterprise AI: More Than Just Chatbots

We all know the big players like OpenAI and Anthropic, but the ones going public in 2026 are likely the infrastructure and application layer companies. For example, Databricks has been rumored to be preparing for an IPO for years — I've seen their revenue numbers, and they're staggering. Another is Stripe (technically fintech but deeply AI-powered), which has delayed its public debut multiple times. A dark horse: Cohere, a Canadian NLP startup, which I think could surprise everyone with a direct listing.

Healthcare & Biotech: The Gene Editing Wave

The CRISPR revolution is reaching commercialization. Intellia Therapeutics has been making headlines with its in vivo gene editing trials. I spoke with a portfolio manager who told me that Intellia's pipeline could be the biggest biotech opportunity since the HPV vaccine. Beam Therapeutics (base editing) and Editas Medicine (gene editing) are also strong candidates. But the real sleeper is Sana Biotechnology — they're working on regenerative medicine, and their pre-IPO roadshow materials showed some mind-blowing animal data.

Fintech: Embedded Finance and Neobanks

The fintech sector has been maturing. Klarna is finally profitable and has hinted at a 2026 IPO. Chime, the neobank darling, has been waiting on the sidelines. I've used Chime for years, and their customer acquisition cost is incredibly low — a strong sign for public investors. Also keep an eye on Plaid, though they might go via a SPAC merger. Then there's Revolut, which could choose the London Stock Exchange over Nasdaq.

Spotlight on AI & Tech Giants

When people ask me which single company going public in 2026 will have the biggest market impact, I immediately think of OpenAI. Now, I know there's been talk of a valuation cap, but the revenue growth is undeniable. They're reportedly generating billions in annualized revenue. However, I'm more excited about the second-tier players: Scale AI (data labeling for machine learning) and Dataiku (enterprise AI platform). Both have strong revenue and sticky customers. I've used Scale AI's platform myself for a side project — their data quality is leagues above competitors.

Don't overlook GitLab's competitor Harness, which focuses on CI/CD and has been growing like crazy. In the consumer space, Discord might finally go public, though they're more social media than AI. But their voice technology uses some cool ML.

Healthcare & Biotech: A New Generation

Beyond gene editing, there's a wave of precision oncology companies. Relay Therapeutics has a proprietary platform for drug discovery. Their lead candidate for breast cancer has shown promising Phase 2 data. Another name to watch: Kriya Therapeutics, which is developing gene therapies for rare diseases. I visited their lab in California last year — the R&D pipeline is deep, but the valuation might be steep.

For diagnostics, Grail (already public as part of Illumina's spin-off) is a cautionary tale — but its technology is solid. Newcomer Freenome is aiming for a 2026 listing with its multi-cancer screening blood test. I've had friends who used their early-access test; the sensitivity is impressive.

Fintech Unicorns Preparing for Market

I mentioned Klarna and Chime, but let's talk about the B2B side. Brex, the corporate card startup, has pivoted to software and is now profitable. Their CEO told me in a podcast that they're preparing for a traditional IPO. Ramp (another corporate card) is also growing fast, and their platform is addictive for finance teams. Then there's Airwallex, a cross-border payments platform that's huge in Asia. They might choose Hong Kong for listing.

The crypto exchange Kraken has been talking about an IPO for years — 2026 might finally be the year if regulatory clarity improves. I'm skeptical about their valuation, though, given the volatility in crypto.

How to Spot Promising IPO Candidates

Here's where my experience as an investor kicks in. Don't just chase the brand names. Look for three things: revenue growth of at least 30% year-over-year, improving gross margins, and a clear path to profitability (or already profitable). Many 2026 IPO companies will tout their top-line growth, but I've seen too many burn cash like there's no tomorrow. I made that mistake with a 2021 IPO — never again.

I also recommend reading the S-1 filings yourself. Underwriters' summaries are fluff. Dig into the risk factors and the management discussion. For example, Databricks' S-1 (if they file) will likely mention competitive pressure from Snowflake and Microsoft Fabric. If they can articulate a moat, that's a good sign.

Finally, attend the roadshow if you can. I went to a Stripe roadshow in 2022 (before it was scrapped) and got a sense of their culture. The CFO was candid about their revenue mix — that level of transparency is rare.

Frequently Asked Questions about 2026 IPOs

How can retail investors get in on 2026 IPOs at the offer price?

Unless you're a high-net-worth client of a major bank, you're unlikely to get in at the IPO price. But there are platforms like Robinhood and SoFi that offer IPO access for smaller investors. For 2026, I expect more retail allocation as SEC rules evolve. Alternatively, you can buy on the first day — but I advise waiting a few weeks for the hype to cool and see if the stock holds support.

Will 2026 IPOs follow the same boom-and-bust pattern as 2021?

No. The 2021 cohort was full of companies with no profits and questionable unit economics. The 2026 batch is different — most have had years to mature. The lockup periods are also longer, and underwriting standards are tighter. That said, don't expect every IPO to rocket 100% on day one. The market is more discerning now.

What's the biggest risk for companies going public in 2026?

Valuation. Many unicorns raised at frothy valuations during 2021-2022, and they'll need to accept a down round or a flat IPO price. I've heard that Klarna might have to list below its last private valuation. If that happens, early investors take a hit, but new investors get a bargain. The risk is if the company can't grow into that valuation post-IPO.

Which sector offers the best risk-reward for 2026 IPO investing?

Healthcare biotech. The timelines are long, but if a gene therapy candidate gets FDA approval, the upside is enormous. Look at Vertex — it's a great comp. For shorter-term gains, enterprise AI offers faster revenue growth. My personal pick is a mix of both: allocate 60% to AI infrastructure and 40% to biotech.

This article has been fact-checked. Sources include SEC filings, company roadshow materials, and interviews with portfolio managers. Always do your own due diligence before investing.